Form 8-K · Current report
TransDigm Group 8-K, filed Sep 14, 2026
- Filed
- CIK
- 0001260221
- Accession no.
- 0001260221-26-000059
Summary
TransDigm Inc., a subsidiary of TransDigm Group, priced $3.0 billion of 6.75% senior secured notes due 2035, upsized from $2.5 billion. TransDigm Group intends to use the net proceeds to repurchase all outstanding 6.75% senior secured notes due 2028 through a concurrent tender offer and for general corporate purposes.
Key points
- TransDigm Inc. priced $3,000 million aggregate principal amount of 6.75% Senior Secured Notes due 2035, increased from an initial $2,500 million.
- The notes will be guaranteed by TransDigm Group and certain of the issuer's direct and indirect subsidiaries and will be issued at 100.00% of principal amount.
- The offering is expected to close on September 28, 2026, subject to customary closing conditions.
- Net proceeds are intended to repurchase all outstanding 6.75% Senior Secured Notes due 2028 via a concurrent tender offer launched on September 14, 2026, and for general corporate purposes.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 7.01Regulation FD Disclosure
From the filing
Item 7.01. Regulation FD Disclosure. Pricing of $3,000 Million Senior Secured Notes Offering On September 14, 2026, TransDigm Group Incorporated (“TransDigm Group”) announced that its wholly-owned subsidiary, TransDigm Inc. (the “Issuer”) priced the previously announced offering of $3,000 million aggregate principal amount of 6.75% Senior Secured Notes due 2035 (the “Notes”), which was increased from the previously announced initial $2,500 million, pursuant to a confidential offering memorandum in a private placement under Rule 144A and Regulation S of the Securities Act of 1933, as amended (the “Securities Act”). …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.